Marie Pronot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marie Pronot has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Michael Alan Cousin
Centre for Discovery Brain Sciences University of Edinburgh Edinburgh UK
4 shared publications - Elizabeth C. Davenport
Centre for Discovery Brain Sciences
3 shared publications - Alfredo Gonzalez-Sulser
Institute for Neuroscience and Cardiovascular Research, Hugh Robson Building, George Square, University of Edinburgh, Edinburgh, Scotland, UK
2 shared publications - Katharine L. Dobson
School of Life Sciences, University of Nottingham Medical School, Nottingham NG7 2UH, UK
2 shared publications - Katherine Bonnycastle
Department of Pediatrics, Genetics Service, Centre Hospitalier Universitaire Sainte-Justine, Montréal, Quebec, Canada
2 shared publications - Moritz Steinruecke
University of Cambridge School of Clinical Medicine, Cambridge, UK
2 shared publications
Latest Publications
- 6 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Régulation et conséquences fonctionnelles de la SUMOylation à la synapse
Les modifications post-traductionnelles sont essentielles à la régulation des fonctions protéiques et, par conséquent, au maintien de l’intégrité cellulaire. Ces modifications interviennent à tous les niveaux de la communication neuronale. Lors de mon doctorat, j’ai étudié l’une de ces modifications, la SUMOylation. Elle consiste en la conjugaison enzymatique covalente mais réversible, de la protéine SUMO (Small Ubiquitin-like MOdifier) sur des résidus lysine spécifiques de protéines cibles. Au cours des dix dernières années, la SUMOylation est apparue comme un régulateur important de la fonction neuronale, jouant un rôle dans le développement du cerveau, l'excitabilité neuronale, la transmission et la plasticité synaptique. Il existe par ailleurs une balance entre l’état SUMOylé et déSUMOylé des protéines cérébrales, permettant une régulation fonctionnelle à la fois dans le temps et dans l’espace. Il est important de noter que les altérations du processus d'homéostasie de la SUMOylation sont associées à une variété de troubles cérébraux. Pour mieux comprendre les fonctions synaptiques de la SUMOylation, il est donc essentiel d’identifier les protéines de la synapse modifiées par SUMO ainsi que de déterminer les mécanismes qui y régulent la balance SUMO/déSUMOylation.Cependant, les mécanismes de régulation restent à élucider et le répertoire disponible des substrats SUMO identifiés au niveau des synapses est encore extrêmement limité. Mon travail de thèse a donc été découpé en deux axes : l’étude de la régulation synaptique de la balance SUMOylation/déSUMOylation et l’identification et la caractérisation d’un SUMOylome à la synapse.La balance SUMOylation/désSUMOylation est maintenue par l'action coordonnée de la seule enzyme de conjugaison SUMO, Ubc9, et des enzymes de déSUMOylation appelées SENP. Nous avons dans unp remier temps démontré qu'une activation brève des récepteurs métabotropique du glutamate mGlu5R piège transitoirement Ubc9 aux post-synapses, ce qui entraîne une augmentation rapide de la SUMOylation synaptique globale et des changements dans l'excitabilité neuronale. Une activation prolongée des récepteurs mGlu5R entraîne une accumulation post-synaptique de SENP1 et une diminution de la SUMOylation synaptique. Étant donné que les deux processus sont contrôlés par l'activation des récepteurs mGlu5R mais sur des échelles de temps différentes, d'autres mécanismes doivent coexister pour réguler cet équilibre au niveau des synapses. En utilisant une combinaison d'imagerie en temps réel et d'approches biochimiques et pharmacologiques, nous avons montré une régulation bidirectionnelle de la déSUMOylation synaptique par les mGluRs du groupe I (mGluR1 et 5) et mis en évidence un rôle de l'activation des kinases PKC et CaMKII ainsi que la polymérisation des microtubules dans la redistribution synaptique de SENP1.En combinant fractionnements subcellulaires à partir de cerveaux de rats post-nataux (P14) et immunoprécipitations SUMO2/3 spécifiques pour isoler les protéines synaptiques SUMO2/3-ylées, nous avons identifié 803 protéines synaptiques SUMOylées. Ces protéines sont importantes pour la fonction synaptique comme par exemple Synapsin3 impliquée dans l’exocytose. Parmi les nouvelles cibles identifiées, on retrouve et SynGAP, ce qui souligne le rôle central de la SUMOylation dans la fonction synaptique. De nombreuses autres protéines identifiées sont directement impliquées dans des troubles neurologiques laissant suggérer une participation du processus de SUMOylation dans l'étiologie de ces maladies cérébrales.Ainsi, mes travaux de thèse ont permis de collecter des informations importantes sur les mécanismes de régulation séquentiels dépendants de l'activité qui conduisent à l'homéostasie de la SUMOylation des protéines au niveau de la synapse et d’établir la première cartographie des cibles SUMO2/3 synaptiques.
- 6 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Régulation et conséquences fonctionnelles de la SUMOylation à la synapse
Les modifications post-traductionnelles sont essentielles à la régulation des fonctions protéiques et, par conséquent, au maintien de l’intégrité cellulaire. Ces modifications interviennent à tous les niveaux de la communication neuronale. Lors de mon doctorat, j’ai étudié l’une de ces modifications, la SUMOylation. Elle consiste en la conjugaison enzymatique covalente mais réversible, de la protéine SUMO (Small Ubiquitin-like MOdifier) sur des résidus lysine spécifiques de protéines cibles. Au cours des dix dernières années, la SUMOylation est apparue comme un régulateur important de la fonction neuronale, jouant un rôle dans le développement du cerveau, l'excitabilité neuronale, la transmission et la plasticité synaptique. Il existe par ailleurs une balance entre l’état SUMOylé et déSUMOylé des protéines cérébrales, permettant une régulation fonctionnelle à la fois dans le temps et dans l’espace. Il est important de noter que les altérations du processus d'homéostasie de la SUMOylation sont associées à une variété de troubles cérébraux. Pour mieux comprendre les fonctions synaptiques de la SUMOylation, il est donc essentiel d’identifier les protéines de la synapse modifiées par SUMO ainsi que de déterminer les mécanismes qui y régulent la balance SUMO/déSUMOylation.Cependant, les mécanismes de régulation restent à élucider et le répertoire disponible des substrats SUMO identifiés au niveau des synapses est encore extrêmement limité. Mon travail de thèse a donc été découpé en deux axes : l’étude de la régulation synaptique de la balance SUMOylation/déSUMOylation et l’identification et la caractérisation d’un SUMOylome à la synapse.La balance SUMOylation/désSUMOylation est maintenue par l'action coordonnée de la seule enzyme de conjugaison SUMO, Ubc9, et des enzymes de déSUMOylation appelées SENP. Nous avons dans unp remier temps démontré qu'une activation brève des récepteurs métabotropique du glutamate mGlu5R piège transitoirement Ubc9 aux post-synapses, ce qui entraîne une augmentation rapide de la SUMOylation synaptique globale et des changements dans l'excitabilité neuronale. Une activation prolongée des récepteurs mGlu5R entraîne une accumulation post-synaptique de SENP1 et une diminution de la SUMOylation synaptique. Étant donné que les deux processus sont contrôlés par l'activation des récepteurs mGlu5R mais sur des échelles de temps différentes, d'autres mécanismes doivent coexister pour réguler cet équilibre au niveau des synapses. En utilisant une combinaison d'imagerie en temps réel et d'approches biochimiques et pharmacologiques, nous avons montré une régulation bidirectionnelle de la déSUMOylation synaptique par les mGluRs du groupe I (mGluR1 et 5) et mis en évidence un rôle de l'activation des kinases PKC et CaMKII ainsi que la polymérisation des microtubules dans la redistribution synaptique de SENP1.En combinant fractionnements subcellulaires à partir de cerveaux de rats post-nataux (P14) et immunoprécipitations SUMO2/3 spécifiques pour isoler les protéines synaptiques SUMO2/3-ylées, nous avons identifié 803 protéines synaptiques SUMOylées. Ces protéines sont importantes pour la fonction synaptique comme par exemple Synapsin3 impliquée dans l’exocytose. Parmi les nouvelles cibles identifiées, on retrouve et SynGAP, ce qui souligne le rôle central de la SUMOylation dans la fonction synaptique. De nombreuses autres protéines identifiées sont directement impliquées dans des troubles neurologiques laissant suggérer une participation du processus de SUMOylation dans l'étiologie de ces maladies cérébrales.Ainsi, mes travaux de thèse ont permis de collecter des informations importantes sur les mécanismes de régulation séquentiels dépendants de l'activité qui conduisent à l'homéostasie de la SUMOylation des protéines au niveau de la synapse et d’établir la première cartographie des cibles SUMO2/3 synaptiques.
- Open Access
- 9 September 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (20)
Prenatal SMN-dependent defects in translation uncover reversible primary cilia phenotypes in spinal muscular atrophy
Spinal muscular atrophy (SMA) is a neuromuscular disease caused by low levels of survival motor neuron (SMN) protein. Several therapeutic approaches boosting SMN are approved for human patients, delivering remarkable improvements in lifespan and symptoms. However, emerging phenotypes, including neurodevelopmental comorbidities, are being reported in some treated patients with SMA, indicative of alterations in brain development. Here, using a mouse model of severe SMA, we revealed an underlying neurodevelopmental phenotype in SMA where prenatal SMN-dependent defects in translation drove disruptions in nonmotile primary cilia across the central nervous system (CNS). Low levels of SMN caused widespread perturbations in translation at E14.5 targeting genes associated with primary cilia. The density of primary cilia in vivo, as well as cilial length in vitro, was significantly decreased in prenatal SMA mice. Proteomic analysis revealed downstream perturbations in primary cilia-regulated signaling pathways, including Wnt signaling. Cell proliferation was concomitantly reduced in the hippocampus of SMA mice. Prenatal transplacental therapeutic intervention with SMN-restoring risdiplam rescued primary cilia defects in SMA mouse embryos. Thus, SMN protein is required for normal cellular and molecular development of primary cilia in the CNS. Early, systemic treatment with SMN-restoring therapies can successfully target neurodevelopmental comorbidities in SMA.
- 9 September 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (20)
Open AccessPrenatal SMN-dependent defects in translation uncover reversible primary cilia phenotypes in spinal muscular atrophy
Spinal muscular atrophy (SMA) is a neuromuscular disease caused by low levels of survival motor neuron (SMN) protein. Several therapeutic approaches boosting SMN are approved for human patients, delivering remarkable improvements in lifespan and symptoms. However, emerging phenotypes, including neurodevelopmental comorbidities, are being reported in some treated patients with SMA, indicative of alterations in brain development. Here, using a mouse model of severe SMA, we revealed an underlying neurodevelopmental phenotype in SMA where prenatal SMN-dependent defects in translation drove disruptions in nonmotile primary cilia across the central nervous system (CNS). Low levels of SMN caused widespread perturbations in translation at E14.5 targeting genes associated with primary cilia. The density of primary cilia in vivo, as well as cilial length in vitro, was significantly decreased in prenatal SMA mice. Proteomic analysis revealed downstream perturbations in primary cilia-regulated signaling pathways, including Wnt signaling. Cell proliferation was concomitantly reduced in the hippocampus of SMA mice. Prenatal transplacental therapeutic intervention with SMN-restoring risdiplam rescued primary cilia defects in SMA mouse embryos. Thus, SMN protein is required for normal cellular and molecular development of primary cilia in the CNS. Early, systemic treatment with SMN-restoring therapies can successfully target neurodevelopmental comorbidities in SMA.
- Open Access
- 1 August 2024
- Published by Wiley in Journal of Neurochemistry
- Vol. 168 (9) , 3188-3208
SV2A controls the surface nanoclustering and endocytic recruitment of Syt1 during synaptic vesicle recycling
Following exocytosis, the recapture of plasma membrane‐stranded vesicular proteins into recycling synaptic vesicles (SVs) is essential for sustaining neurotransmission. Surface clustering of vesicular proteins has been proposed to act as a ‘pre‐assembly’ mechanism for endocytosis that ensures high‐fidelity retrieval of SV cargo. Here, we used single‐molecule imaging to examine the nanoclustering of synaptotagmin‐1 (Syt1) and synaptic vesicle protein 2A (SV2A) in hippocampal neurons. Syt1 forms surface nanoclusters through the interaction of its C2B domain with SV2A, which are sensitive to mutations in this domain (Syt1K326A/K328A) and SV2A knockdown. SV2A co‐clustering with Syt1 is reduced by blocking SV2A's cognate interaction with Syt1 (SV2AT84A). Surprisingly, impairing SV2A‐Syt1 nanoclustering enhanced the plasma membrane recruitment of key endocytic protein dynamin‐1, causing accelerated Syt1 endocytosis, altered intracellular sorting and decreased trafficking of Syt1 to Rab5‐positive endocytic compartments. Therefore, SV2A and Syt1 are segregated from the endocytic machinery in surface nanoclusters, limiting dynamin recruitment and negatively regulating Syt1 entry into recycling SVs. image
- 1 August 2024
- Published by Wiley in Journal of Neurochemistry
- Vol. 168 (9) , 3188-3208
Open AccessSV2A controls the surface nanoclustering and endocytic recruitment of Syt1 during synaptic vesicle recycling
Following exocytosis, the recapture of plasma membrane‐stranded vesicular proteins into recycling synaptic vesicles (SVs) is essential for sustaining neurotransmission. Surface clustering of vesicular proteins has been proposed to act as a ‘pre‐assembly’ mechanism for endocytosis that ensures high‐fidelity retrieval of SV cargo. Here, we used single‐molecule imaging to examine the nanoclustering of synaptotagmin‐1 (Syt1) and synaptic vesicle protein 2A (SV2A) in hippocampal neurons. Syt1 forms surface nanoclusters through the interaction of its C2B domain with SV2A, which are sensitive to mutations in this domain (Syt1K326A/K328A) and SV2A knockdown. SV2A co‐clustering with Syt1 is reduced by blocking SV2A's cognate interaction with Syt1 (SV2AT84A). Surprisingly, impairing SV2A‐Syt1 nanoclustering enhanced the plasma membrane recruitment of key endocytic protein dynamin‐1, causing accelerated Syt1 endocytosis, altered intracellular sorting and decreased trafficking of Syt1 to Rab5‐positive endocytic compartments. Therefore, SV2A and Syt1 are segregated from the endocytic machinery in surface nanoclusters, limiting dynamin recruitment and negatively regulating Syt1 entry into recycling SVs. image
- Open Access
Molecular Organization and Regulation of the Mammalian Synapse by the Post-Translational Modification SUMOylation
Neurotransmission occurs within highly specialized compartments forming the active synapse where the complex organization and dynamics of the interactions are tightly orchestrated both in time and space. Post-translational modifications (PTMs) are central to these spatiotemporal regulations to ensure an efficient synaptic transmission. SUMOylation is a dynamic PTM that modulates the interactions between proteins and consequently regulates the conformation, the distribution and the trafficking of the SUMO-target proteins. SUMOylation plays a crucial role in synapse formation and stabilization, as well as in the regulation of synaptic transmission and plasticity. In this review, we summarize the molecular consequences of this protein modification in the structural organization and function of the mammalian synapse. We also outline novel activity-dependent regulation and consequences of the SUMO process and explore how this protein modification can functionally participate in the compartmentalization of both pre- and post-synaptic sites.
Open AccessMolecular Organization and Regulation of the Mammalian Synapse by the Post-Translational Modification SUMOylation
Neurotransmission occurs within highly specialized compartments forming the active synapse where the complex organization and dynamics of the interactions are tightly orchestrated both in time and space. Post-translational modifications (PTMs) are central to these spatiotemporal regulations to ensure an efficient synaptic transmission. SUMOylation is a dynamic PTM that modulates the interactions between proteins and consequently regulates the conformation, the distribution and the trafficking of the SUMO-target proteins. SUMOylation plays a crucial role in synapse formation and stabilization, as well as in the regulation of synaptic transmission and plasticity. In this review, we summarize the molecular consequences of this protein modification in the structural organization and function of the mammalian synapse. We also outline novel activity-dependent regulation and consequences of the SUMO process and explore how this protein modification can functionally participate in the compartmentalization of both pre- and post-synaptic sites.
- Open Access
- 30 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-19
Reversal of cell, circuit and seizure phenotypes in a mouse model of DNM1 epileptic encephalopathy
Dynamin-1 is a large GTPase with an obligatory role in synaptic vesicle endocytosis at mammalian nerve terminals. Heterozygous missense mutations in the dynamin-1 gene (DNM1) cause a novel form of epileptic encephalopathy, with pathogenic mutations clustering within regions required for its essential GTPase activity. We reveal the most prevalent pathogenic DNM1 mutation, R237W, disrupts dynamin-1 enzyme activity and endocytosis when overexpressed in central neurons. To determine how this mutation impacted cell, circuit and behavioural function, we generated a mouse carrying the R237W mutation. Neurons from heterozygous mice display dysfunctional endocytosis, in addition to altered excitatory neurotransmission and seizure-like phenotypes. Importantly, these phenotypes are corrected at the cell, circuit and in vivo level by the drug, BMS-204352, which accelerates endocytosis. Here, we demonstrate a credible link between dysfunctional endocytosis and epileptic encephalopathy, and importantly reveal that synaptic vesicle recycling may be a viable therapeutic target for monogenic intractable epilepsies.
- 30 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-19
Open AccessReversal of cell, circuit and seizure phenotypes in a mouse model of DNM1 epileptic encephalopathy
Dynamin-1 is a large GTPase with an obligatory role in synaptic vesicle endocytosis at mammalian nerve terminals. Heterozygous missense mutations in the dynamin-1 gene (DNM1) cause a novel form of epileptic encephalopathy, with pathogenic mutations clustering within regions required for its essential GTPase activity. We reveal the most prevalent pathogenic DNM1 mutation, R237W, disrupts dynamin-1 enzyme activity and endocytosis when overexpressed in central neurons. To determine how this mutation impacted cell, circuit and behavioural function, we generated a mouse carrying the R237W mutation. Neurons from heterozygous mice display dysfunctional endocytosis, in addition to altered excitatory neurotransmission and seizure-like phenotypes. Importantly, these phenotypes are corrected at the cell, circuit and in vivo level by the drug, BMS-204352, which accelerates endocytosis. Here, we demonstrate a credible link between dysfunctional endocytosis and epileptic encephalopathy, and importantly reveal that synaptic vesicle recycling may be a viable therapeutic target for monogenic intractable epilepsies.
- Open Access
Reversal of cell, circuit and seizure phenotypes in a mouse model of DNM1 epileptic encephalopathy
Pathogenic heterozygous missense mutations in the DNM1 gene result in a novel form of epileptic encephalopathy. DNM1 encodes for the large GTPase dynamin-1, an enzyme with an obligatory role in the endocytosis of synaptic vesicles (SVs) at mammalian nerve terminals. Pathogenic DNM1 mutations cluster within regions required for its essential GTPase activity, implicating disruption of this enzyme activity as being central to epileptic encephalopathy. We reveal that the most prevalent pathogenic mutation of DNM1 , R237W, disrupts dynamin-1 enzyme activity and SV endocytosis when overexpressed in central neurons. To determine how this dominant-negative heterozygous mutant impacted cell, circuit and behaviour when expressed from its endogenous locus, we generated a mouse carrying the R237W mutation. Neurons isolated from heterozygous mice displayed dysfunctional SV endocytosis, which translated into altered excitatory neurotransmission and seizure-like phenotypes. Importantly, these phenotypes were corrected at the cell, circuit and in vivo level by the drug, BMS-204352, which accelerates SV endocytosis. This study therefore provides the first direct link between dysfunctional SV endocytosis and epilepsy, and importantly reveals that SV endocytosis is a viable therapeutic route for monogenic intractable epilepsies.
Open AccessReversal of cell, circuit and seizure phenotypes in a mouse model of DNM1 epileptic encephalopathy
Pathogenic heterozygous missense mutations in the DNM1 gene result in a novel form of epileptic encephalopathy. DNM1 encodes for the large GTPase dynamin-1, an enzyme with an obligatory role in the endocytosis of synaptic vesicles (SVs) at mammalian nerve terminals. Pathogenic DNM1 mutations cluster within regions required for its essential GTPase activity, implicating disruption of this enzyme activity as being central to epileptic encephalopathy. We reveal that the most prevalent pathogenic mutation of DNM1 , R237W, disrupts dynamin-1 enzyme activity and SV endocytosis when overexpressed in central neurons. To determine how this dominant-negative heterozygous mutant impacted cell, circuit and behaviour when expressed from its endogenous locus, we generated a mouse carrying the R237W mutation. Neurons isolated from heterozygous mice displayed dysfunctional SV endocytosis, which translated into altered excitatory neurotransmission and seizure-like phenotypes. Importantly, these phenotypes were corrected at the cell, circuit and in vivo level by the drug, BMS-204352, which accelerates SV endocytosis. This study therefore provides the first direct link between dysfunctional SV endocytosis and epilepsy, and importantly reveals that SV endocytosis is a viable therapeutic route for monogenic intractable epilepsies.
- Open Access
- 3 June 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-19
A synaptomic analysis reveals dopamine hub synapses in the mouse striatum
Dopamine transmission is involved in reward processing and motor control, and its impairment plays a central role in numerous neurological disorders. Despite its strong pathophysiological relevance, the molecular and structural organization of the dopaminergic synapse remains to be established. Here, we used targeted labelling and fluorescence activated sorting to purify striatal dopaminergic synaptosomes. We provide the proteome of dopaminergic synapses with 57 proteins specifically enriched. Beyond canonical markers of dopamine neurotransmission such as dopamine biosynthetic enzymes and cognate receptors, we validated 6 proteins not previously described as enriched. Moreover, our data reveal the adhesion of dopaminergic synapses to glutamatergic, GABAergic or cholinergic synapses in structures we named “dopamine hub synapses”. At glutamatergic synapses, pre- and postsynaptic markers are significantly increased upon association with dopamine synapses. Dopamine hub synapses may thus support local dopaminergic signalling, complementing volume transmission thought to be the major mechanism by which monoamines modulate network activity.
- 3 June 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-19
Open AccessA synaptomic analysis reveals dopamine hub synapses in the mouse striatum
Dopamine transmission is involved in reward processing and motor control, and its impairment plays a central role in numerous neurological disorders. Despite its strong pathophysiological relevance, the molecular and structural organization of the dopaminergic synapse remains to be established. Here, we used targeted labelling and fluorescence activated sorting to purify striatal dopaminergic synaptosomes. We provide the proteome of dopaminergic synapses with 57 proteins specifically enriched. Beyond canonical markers of dopamine neurotransmission such as dopamine biosynthetic enzymes and cognate receptors, we validated 6 proteins not previously described as enriched. Moreover, our data reveal the adhesion of dopaminergic synapses to glutamatergic, GABAergic or cholinergic synapses in structures we named “dopamine hub synapses”. At glutamatergic synapses, pre- and postsynaptic markers are significantly increased upon association with dopamine synapses. Dopamine hub synapses may thus support local dopaminergic signalling, complementing volume transmission thought to be the major mechanism by which monoamines modulate network activity.